Crizotinib Hydrochloride: ATP-Competitive ALK, c-Met, and ROS1 Kinase Inhibitor for Cancer Research

Executive Summary: Crizotinib hydrochloride is a small molecule inhibitor designed for selective, ATP-competitive inhibition of ALK, c-Met, and ROS1 kinases in cancer research settings (APExBIO). It exhibits high solubility in DMSO (≥100.4 mg/mL), ethanol (≥101.4 mg/mL), and water (≥52.2 mg/mL) and maintains purity levels above 98% by HPLC and NMR. Crizotinib hydrochloride effectively inhibits phosphorylation of ALK and c-Met at low nanomolar concentrations in vitro, disrupting oncogenic kinase signaling pathways (Shapira-Netanelov et al., 2025). This compound is utilized in advanced assembloid models for exploring tumor–stroma interactions and resistance mechanisms. The B3608 kit from APExBIO is routinely integrated into cancer biology workflows for robust, reproducible kinase inhibition studies.

Biological Rationale

Crizotinib hydrochloride (CAS 1415560-69-8) targets three critical kinases: ALK (anaplastic lymphoma kinase), c-Met (hepatocyte growth factor receptor), and ROS1. These kinases are frequently dysregulated in various malignancies, including non-small cell lung cancer (NSCLC) and subsets of gastric cancer (Shapira-Netanelov et al., 2025). Aberrant activation of ALK or ROS1 often results from gene rearrangements or overexpression, leading to constitutive signaling and uncontrolled cellular proliferation. c-Met activation, commonly by ligand-dependent or -independent mechanisms, contributes to tumor progression and metastasis. Kinase-driven signaling cascades, particularly involving NPM-ALK fusion proteins and phosphorylated c-Met receptors, are established drivers of oncogenic transformation and therapeutic resistance. By targeting these kinases, Crizotinib hydrochloride enables researchers to dissect the molecular underpinnings of oncogenic signaling in physiologically relevant models, especially patient-derived assembloids that recapitulate tumor heterogeneity and microenvironmental complexity (see detailed assembloid dissection).

Mechanism of Action of Crizotinib Hydrochloride

Crizotinib hydrochloride is an orally bioavailable, ATP-competitive small molecule inhibitor. It selectively binds to the ATP-binding sites of ALK, c-Met, and ROS1 kinases, thereby blocking their catalytic activity. This inhibition prevents autophosphorylation and subsequent activation of downstream signaling pathways such as PI3K/AKT, RAS/RAF/MEK/ERK, and STAT3, which are essential for cell proliferation, survival, and migration. In vitro, Crizotinib hydrochloride effectively reduces the phosphorylation status of both c-Met receptors and NPM-ALK fusion proteins at low nanomolar concentrations (typically IC₅₀ values in the range of 20–40 nM for ALK/c-Met; buffer: PBS, pH 7.4, 37°C, 1 h incubation). This leads to the suppression of oncogenic growth signals and induces apoptosis in kinase-dependent cancer cells (Shapira-Netanelov et al., 2025; see precision application in assembloid models). Crizotinib hydrochloride’s specificity also permits the study of resistance mechanisms arising from stromal-epithelial interactions within complex tumor models.

Evidence & Benchmarks

• Crizotinib hydrochloride inhibits ALK and c-Met phosphorylation at nanomolar concentrations in cell-based assays, as verified by immunofluorescence and Western blot analyses (Shapira-Netanelov et al., 2025).
• Patient-derived gastric cancer assembloids treated with Crizotinib hydrochloride show reduced viability in kinase-driven tumor subpopulations compared to untreated controls (Shapira-Netanelov et al., 2025).
• Integration of autologous stromal cell populations in assembloids modulates drug response, revealing variable sensitivity to Crizotinib hydrochloride and highlighting the importance of the tumor microenvironment in resistance (Shapira-Netanelov et al., 2025).
• The compound is stable at -20°C and maintains >98% purity for at least 12 months under recommended storage conditions (APExBIO).
• Solubility benchmarks: ≥100.4 mg/mL in DMSO, ≥101.4 mg/mL in ethanol, ≥52.2 mg/mL in water (room temperature, pH 7.4) (APExBIO).

This article builds upon the mechanistic insights provided in "Crizotinib Hydrochloride: Unlocking Stromal Complexity" by detailing quantitative benchmarks and the impact of microenvironmental factors on drug response, not previously addressed in depth.

Applications, Limits & Misconceptions

Crizotinib hydrochloride is extensively used in preclinical cancer research, particularly for:

• Modeling ALK or ROS1-driven oncogenic signaling in patient-derived organoids and assembloids.
• Elucidating mechanisms of kinase inhibitor resistance within physiologically relevant tumor microenvironments (Shapira-Netanelov et al., 2025).
• Optimizing combination therapies and drug screening protocols in gastric, lung, and other cancers with aberrant kinase activation.
• Standardizing kinase inhibition workflows due to its high purity and lot-to-lot consistency (APExBIO).

While Crizotinib hydrochloride is a cornerstone for probing oncogenic kinase networks, its efficacy and selectivity are context-dependent. For example, in assembloid models containing diverse stromal cell subtypes, drug response may be diminished due to microenvironment-mediated resistance. This nuance is explored in "Crizotinib Hydrochloride in Patient-Derived Assembloids", which this article extends by providing quantitative solubility and purity data.

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: Crizotinib hydrochloride exhibits high selectivity for ALK, c-Met, and ROS1, but does not broadly inhibit all tyrosine kinases.
• Cellular context matters: Efficacy can drop in assembloids with abundant stromal populations due to paracrine resistance factors; results from monoculture systems may not translate directly (Shapira-Netanelov et al., 2025).
• Not FDA-approved for all cancers: Clinical approvals are limited to specific indications (e.g., ALK-positive NSCLC); use in other models is strictly for research.
• Solution stability: Long-term storage of dissolved Crizotinib hydrochloride (i.e., >1 week in DMSO or water) can reduce potency due to hydrolysis; fresh solutions are recommended (APExBIO).

Workflow Integration & Parameters

Crizotinib hydrochloride (B3608, APExBIO) is supplied as a stable, lyophilized powder with a molecular weight of 486.8 g/mol and chemical formula C₂₁H₂₃Cl₃FN₅O. For optimal results:

• Dissolve in DMSO (≥100.4 mg/mL), ethanol (≥101.4 mg/mL), or water (≥52.2 mg/mL) at room temperature, pH ~7.4.
• Aliquot and store stock solutions at -20°C; minimize freeze-thaw cycles.
• Prepare working dilutions fresh prior to each experiment to maintain inhibitory activity.
• Recommended concentration range for kinase inhibition in cell-based assays: 10–100 nM, depending on model.
• Confirm activity by monitoring ALK/c-Met phosphorylation via Western blot or immunofluorescence.

Detailed procedures and troubleshooting guides are available on the Crizotinib hydrochloride product page. This article updates earlier workflow protocols described in "Crizotinib Hydrochloride: ATP-Competitive ALK, c-Met, and..." by providing explicit solubility and storage thresholds for reproducible results.

Conclusion & Outlook

Crizotinib hydrochloride remains an essential reagent for elucidating kinase-driven oncogenic signaling in cancer research. Its validated performance in advanced assembloid models positions it as a gold standard for dissecting resistance mechanisms and optimizing personalized therapeutic strategies. As patient-derived systems continue to evolve, the integration of context-specific inhibitors such as Crizotinib hydrochloride will be critical for advancing translational oncology and precision medicine. For complete technical specifications and ordering information, see the APExBIO Crizotinib hydrochloride B3608 kit.